Sugi Predict

Sugi Predict / Compounds / SCHEMBL4020818

SCHEMBL4020818

SCHEMBL4020818

CS(=O)(=O)c1n[c]c2c(-c3ccccc3Cl)nn(C(N)=O)c2n1

nearest known ligand 0.38

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ MAPK14 Q16539 1/20 0.38
▸ SCN9A Q15858 2/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ SLC9A1 P19634 1/20 0.34
▸ HSD11B1 P28845 2/20 0.33
▸ PTGS2 P35354 2/20 0.33
▸ KMT2A Q03164 2/20 0.33
▸ MAPT P10636 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.31
▸ ADORA2A P29274 1/20 0.31
▸ ADORA1 P30542 1/20 0.31
▸ IKBKB O14920 1/20 0.31
▸ PLAU P00749 1/20 0.31
▸ ELANE P08246 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4013981 0.83 HSP90AA1 (0.41) MAPK14SCN9AHSD17B10KMT2AMAPT
SCHEMBL6016411 0.61 L3MBTL1 (0.50) MAPK14L3MBTL1HSD17B10PTGS2KMT2A
SCHEMBL4020816 0.61 SLC9A1 (0.42) MAPK14L3MBTL1HSD17B10SLC9A1HSD11B1
SCHEMBL1065189 0.59 MAPK14 (0.44) MAPK14L3MBTL1HSD11B1KMT2AALDH1A1
SCHEMBL6866618 0.58 MAPT (0.49) L3MBTL1HSD17B10KMT2AMAPTALDH1A1
SCHEMBL4020823 0.57 MAPK14 (0.42) MAPK14L3MBTL1SLC9A1HSD11B1PTGS2
SCHEMBL4083936 0.57 RIPK2 (0.65) MAPK14
SCHEMBL4606713 0.57 PTGS2 (0.46) MAPK14L3MBTL1HSD17B10HSD11B1PTGS2
SCHEMBL6884800 0.56 L3MBTL1 (0.43) MAPK14L3MBTL1HSD17B10HSD11B1PTGS2
SCHEMBL5909609 0.55 LMNA (0.34) HSD17B10MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7566708-B2 Substituted pyrazolo{3,4-D}pyrimidines as p38 map kinase inhibitors ROCHE PALO ALTO LLC (US) 2009-07-28 — — US disclosed
US-7435731-B2 Substituted pyrazolo[3,4-d]pyrimadines and methods of using the same ROCHE PALO ALTO LLC (US) 2008-10-14 — — US disclosed
EP-1919470-A1 FUSED PYRAZOLE AS p38 MAP KINASE INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2008-05-14 — — EP disclosed
US-20070203160-A1 p38 MAP kinase inhibitors and methods for using the same ROCHE PALO ALTO LLC 2007-08-30 — — US disclosed
WO-2007023105-A1 FUSED PYRAZOLE AS p38 MAP KINASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2007-03-01 — — WO disclosed
EP-1737865-A1 FUSED DERIVATIVES OF PYRAZOLE F.HOFFMANN-LA ROCHE AG (CH) 2007-01-03 — — EP disclosed
WO-2005085249-A1 FUSED DERIVATIVES OF PYRAZOLE F. HOFFMANN-LA ROCHE AG (CH) 2005-09-15 — — WO disclosed
US-20050197340-A1 Fused-pyrazolo pyrimidine and pyrazolo pyrimidinone derivatives and methods for using the same ROCHE PALO ALTO LLC 2005-09-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197340-A1 Fused-pyrazolo pyrimidine and pyrazolo pyrimidinone derivatives and methods for using the same MAP3K1, MAPK1, MAP3K8 MAPK14 70/4885SCN9A 4259/4885L3MBTL1 3443/4885
US-20070203160-A1 p38 MAP kinase inhibitors and methods for using the same MAPKAPK2, MAPK1, MAP3K2 MAPK14 33/4885SCN9A 4565/4885L3MBTL1 727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.